Home / Drug discovery / ADME / In vitro ADME
In vitro ADME drug discovery services
To enable you to make faster, smarter decisions during early discovery, our in vitro ADME services provide timely insights into compound behavior across absorption, distribution, metabolism, and excretion.
We generate fast, decision-ready ADME data – from PK and permeability to metabolic stability and protein binding – to guide lead selection and reduce downstream risk.
Our services are available for small molecules, peptides, oligonucleotides, ADCs, PROTACs, pro-drugs and other modalities.
Services include:
- Physicochemical profiling – Investigate solubility, lipophilicity, and chemical stability
- Metabolic stability studies – Evaluate compound stability in liver microsomes, hepatocytes, plasma or other relevant biomatrices, including systems for low clearance compounds
- Metabolite profiling and identification – Characterize metabolic soft spots, full metabolite profiles, cross-species comparison to support lead optimization and tox-species selection
- Cytochrome P450 profiling and non-CYP phenotyping – Conduct phenotyping, inhibition and induction assays to evaluate potential drug-drug interactions
- Plasma protein binding assays – Measure binding characteristics to inform pharmacokinetic behavior
- Permeability and transporter assays – Assess in vitro permeability, involvement of active transport and transporter-mediated drug interactions
- Tailored assay design – Phase-appropriate study design for discovery and regulatory needs
Related services
ADME services delivered by Admescope
All ADME services, including in vitro ADME, in vivo PK screening, in vitro toxicology, in vitro ADME-Tox and in vivo DMPK are performed by Admescope (a Symeres company)
In vitro ADME for speed, clarity and confidence
Discovery to IND, uninterrupted
Linked assays prevent data gaps and rework across early discovery and development.
Built for
your stage
Choose high-throughput screens or detailed packages matched to program goals.
Science
that speaks
ADME data interpreted in context with chemistry and biology for decisions you can rely and build on.
Integrated ADME capabilities
In vitro ADME is part of a connected portfolio that combines in vivo PK and in vitro toxicology for faster insight and early risk detection.
Linked data across studies keeps your results comparable and decisions confident from discovery to IND.
What do our partners say?
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
Your discovery and development partner
Symeres supports small-molecule programs from discovery through IND with openness, agility and scientific depth.
Our connected teams in Europe and North America share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous.
Resources we think you'll love
Blog
CDMO red flags you can’t ignore: Communication breakdowns
Blog
CDMO red flags you can’t ignore: Capacity constraints and resource stretch
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our in vitro ADME experts
Let us support the discovery and development of your next breakthrough.